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A Systematic Review and Meta-analysis of the Literature:
Chemotherapy and Surgery versus Surgery Alone in
Non-small Cell Lung Cancer
Sarah Burdett, MSc, Lesley A. Stewart, PhD, and Larysa Rydzewska, BSc
Background: The effectiveness of preoperative chemotherapy in
the treatment of non-small cell lung cancer has remained unclear
despite the conduct of several randomized controlled trials (RCTs).
Methods: A systematic review and meta-analysis was carried out to
assess the effectiveness of preoperative chemotherapy in non-small
cell lung cancer. This involved identifying eligible RCTs and ex-
tracting aggregate data from the abstracts or reports of these RCTs.
Hazard ratios were calculated from these published summary statis-
tics and then combined to give pooled estimates of treatment
efficacy.
Results: Twelve eligible RCTs were identified, from which data
from seven RCTs, including 988 patients (75% of eligible patients),
could be combined in a systematic review and meta-analysis. Pre-
operative chemotherapy improved survival with a hazard ratio of
0.82 (95% confidence interval, 0.69–0.97; p  0.02). This is
equivalent to an absolute benefit of 6%, increasing overall survival
across all stages of disease from 14% to 20% at 5 years. There was
no evidence of statistical heterogeneity.
Conclusions: This analysis shows a significant benefit of preoper-
ative chemotherapy and is currently the best estimate of the effec-
tiveness of this therapy, but this is based on a small number of trials
and patients. This current analysis was unable to address important
questions such as whether particular types of patients may benefit
more or less from preoperative chemotherapy or whether the early
stopping of a number of included RCTs impacted on the results. To
assess this, an individual patient data meta-analysis is required.
Key Words: Non-small cell lung cancer, Chemotherapy, Surgery,
Systematic review.
(J Thorac Oncol. 2006;1: 611–621)
Worldwide, more than 1 million new cases of lung cancerare diagnosed each year,1 approximately 80% of which
are of non-small cell type,2 comprising adenocarcinomas,
squamous cell carcinomas, and large cell carcinomas. Many
patients are diagnosed when they already have an advanced
form of the disease and, as a consequence, 5-year survival
across all stages of disease is approximately 14%.3 Surgery is
generally regarded as the best treatment option, but only
approximately 25% of non-small cell lung cancer (NSCLC)
tumors are suitable for potentially curative resection.4 A
further 20% of patients with locally advanced disease un-
dergo radical thoracic radiotherapy. The remaining patients,
with late-stage or metastatic disease, are usually treated
palliatively.
The role of chemotherapy in treating NSCLC has been
extensively tested in clinical trials since the 1960s, and
chemotherapy has been reported as being both beneficial and
detrimental. An individual patient data (IPD) meta-analysis5
published in 1995, which is currently being updated,6 found
some evidence that chemotherapy given after surgery may
improve survival. However, this project did not explore the
use of chemotherapy given before surgery, as few trials had
been completed at that time.
The proposed benefits of preoperative chemotherapy
are a reduction in tumor size such that tumors become easier
to remove surgically, and inoperable tumors becoming po-
tentially operable. Preoperative chemotherapy may also assist
the early eradication of metastases that are clinically unde-
tectable, which could lead to better control of distant recur-
rence. Chemotherapy given before surgery may also be better
tolerated than postoperative chemotherapy, as the patient is
more able to cope with side effects when not recovering from
major surgery.
There are, however, proposed disadvantages to this
treatment. While the patient is receiving chemotherapy, a
potentially curative operation is being delayed. If the chemo-
therapy being given is ineffective or only minimally effec-
tive, this delay could prove detrimental and could lead to the
disease spreading.7–9
Preoperative chemotherapy has shown a benefit in other
disease areas. An IPD meta-analysis of preoperative chemo-
therapy in invasive bladder cancer10 has shown a 14% rela-
tive improvement in overall survival (p  0.003) for patients
receiving the treatment, and a systematic review of published
aggregate data regarding esophageal cancer11 showed a sig-
nificant benefit of the treatment at 5 years (p  0.02).
PATIENTS AND METHODS
At the outset, a search of MEDLINE (1966–2005) and
the Cochrane Library12 established that no systematic review
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of preoperative chemotherapy in patients with NSCLC had
already been carried out and a protocol for this systematic
review was written (available on request). This specified
eligibility criteria such that included trials had to be properly
randomized (i.e., in a way that precluded prior knowledge of
treatment assigned), be unconfounded by differences between
treatment arms, have included patients with NSCLC, and
have compared first-line chemotherapy followed by surgery
with surgery alone. Trials of patients who had received
chemotherapy as second-line treatment or who had a previous
malignancy were excluded, and there were no language
restrictions.
Published randomized controlled trials (RCTs) were
found by searching MEDLINE (1966–2005) and the Co-
chrane Library using established search strategies.13 Unpub-
lished and ongoing trials were found by searching a selection of
Trial Registers (cancer.gov, the metaRegister, clinicaltrials.gov,
and the UK Coordinating Committee on Cancer Research
National Register of Cancer Trials). The proceedings of the
largest international meetings in oncology were searched for
trials published only as abstracts. Reference lists of relevant
publications and book chapters were also searched. Searches
were carried out in November of 2004 and August of 2005.
Results of the searches are displayed in Figure 1.14
Eligible RCTs were assessed for quality using a com-
ponent approach. This involved assessing the methodologic
aspects of each trial using the CONSORT15 statement as a
guide to which variables to assess. Data were extracted
independently by two researchers, and any anomalies were
resolved by discussion.
The primary endpoint was overall survival, with
planned additional endpoints of local recurrence-free sur-
vival, distant recurrence-free survival, and overall recurrence-
free survival. Where possible, analyses included all reported
randomized patients.
For meta-analyses of the time-to-event outcomes, the
most appropriate statistic is the hazard ratio (HR). If provided
in a trial report, the HR and associated variances were used
directly in the meta-analysis. Alternatively, using the meth-
ods described by Parmar et al.,16 they were estimated indi-
rectly from other summary statistics (95% confidence inter-
vals [CI], p values, total number of events) or from data
extracted from published Kaplan-Meier curves.16 In the latter
method, the numbers at risk are adjusted (reduced), where
appropriate, to allow for immature follow-up. Where feasible,
a number of methods were used to indirectly estimate the trial
HR to check its reliability. The estimated log HR and vari-
ance were then combined across all trials using the fixed
effect model to give a pooled HR.17 This represents the
overall risk of an event on preoperative chemotherapy and
surgery versus surgery alone.
Overall survival was estimated primarily using the
fixed effect model, with the random effects model used as a
sensitivity analysis. Absolute differences at relevant time
points were calculated by multiplying the log of the baseline
event rate for patients not allocated preoperative chemother-
apy by the hazard ratio. This value was then subtracted from
the baseline event rate to give a percentage improvement or
detriment in the outcome. Confidence intervals for absolute
differences were similarly calculated from the baseline event
rate and the hazard ratio at the 95% confidence interval
boundary values.
The 2 heterogeneity test was used to test for gross
statistical heterogeneity. The I2 statistic18 was used as a
measure of consistency between trials. Where appropriate, a
test for interaction was carried out to see whether there was
any difference between subgroups of trials being compared.
Tests for publication bias were carried out.
RESULTS
Searches identified 12 eligible rcts19–30 (1310 patients)
that were assessed for methodologic quality. No RCTs gave
full details of randomization. Four20,21,23,27 reported random-
izing patients centrally through a data center and the remain-
ing eight simply reported being “randomized.” No trials
reported concealment of allocation, but two21,22 used a cen-
tral telephone, and would imply a level of allocation conceal-
ment. Two trials reported details of their stratification fac-
tors.21,29 Three RCTs20,23,29 described their sample size
calculations, and the remainder did not report any of these
factors.
Eight RCTs did not reach their planned accrual for a
variety of reasons. Three23,25,27 closed early because of poor
accrual, three19–21 because of a significant difference between
the treatments being tested in the trial, and two29,30 because of
the results of other trials. It was unclear whether one trial27
reached its target accrual, as the only publication of this RCT
is the report of interim analyses. The remaining three tri-
als22,24,26 appear to have reached their target accrual.FIGURE 1. Results of searches for RCTs.
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TABLE 1. Characteristics of Eligible Trials*
Trial Recruitment
No. of
Patients Chemotherapy
Additional
Treatment
Extent of
Resection
Disease
Stage†
Informed
Consent
Sought
Data
Extraction
Possible
Dautzenberg et al.,
199019
1985–1987 26 Cisplatin,
cyclophosphamide,
vindesine
Postoperative
chemotherapy on
preoperative
chemotherapy arm
only
Complete and
incomplete
I, II, III No Yes
Roth et al., 199420 1987–1993 60 Cisplatin,
cyclophosphamide,
etoposide
If patients responded
to preoperative
chemotherapy, 3
cycles given
postoperatively
Complete and
incomplete
IIIa Yes Yes
Rosell et al., 199421 1989–1991 60 Cisplatin, mitomycin,
ifosfamide
Postoperative RT on
both arms
Complete and
incomplete
IIIa Yes Yes
Depierre et al.,
200222
1991–1997 373 Cisplatin, mitomycin,
ifosfamide
If surgery
incomplete,
patients received
postoperative RT
(all patients) or
chemotherapy
(preoperative
chemotherapy
patients only)
Complete and
incomplete
I, II, IIIa Yes Yes
JCOG 9209, 200323 1993–1998 62 Cisplatin, vindesine If surgery incomplete
patients received
postoperative RT
on both arms
Complete and
incomplete
IIIa Yes Yes
De Boer et al.,
199924
1995–1997 22 Cisplatin, mitomycin,
vinblastine
NR Complete and
incomplete
Ib, II, IIIa Yes No
MRC BLT,200425 1995–2001 13 Cisplatin, mitomycin,
ifosfamide
or Cisplatin, mitomycin,
vinblastine
or Cisplatin, vindesine
or Cisplatin, vinorelbine
RT given to 14%
patients but no
split between
preoperative/
postoperative
chemotherapy
patients
Complete and
incomplete
I, II, III Yes No
Yi et al., 200326 1998–2001 84 Cisplatin, mitomycin,
vindesine
Postoperative
chemotherapy on
preoperative
chemotherapy arm
only
Unknown I, II, III NR No
Sorensen et al.,
200527
1998–2004 90 Carboplatin, paclitaxel If surgery
incomplete,
patients received
postoperative RT
on both arms
Complete and
incomplete
Ia, IIa, IIb,
IIIa/T3
NR Yes
Wu et al., 200228 1999–? 48 Carboplatin, docetaxel If surgery
incomplete,
patients received
postoperative RT
on both arms
Complete and
incomplete
IIIa NR No
SWOG S9900,
200529
1999–2004 354 Carboplatin, paclitaxel NR At least
lobectomy and
mediastinal
nodal sampling
Ib, II, IIIa Yes Yes
ChE.S.T, 200530 2000–2004 236 Cisplatin, gemcitabine NR Ib, IIa, IIb,
IIIa
NR No
*Trials are ordered by dates of patient recruitment. †Disease stage as reported in the publications; no allowances have been made for changes to staging system. NR, not recorded;
RT, radiotherapy.
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Only two RCTs22,29 reported patient exclusions. They
are the two largest RCTs identified for inclusion in the
systematic review, and both excluded approximately 5% of
patients before analysis. In both trials, all exclusions were
because of patients being found to be ineligible after random-
ization.
Two RCTs24,28 did not report which endpoints had been
analyzed. Ten RCTs19–23,25–27,29,30 analyzed the endpoint of
overall survival. One RCT19 analyzed the endpoint of dis-
ease-free interval, five RCTs21–23,25,27 analyzed disease-free
survival, and three25,29,30 analyzed progression-free survival.
Definitions of how the endpoints were calculated were given
for four RCTs.21–23,25 The methods of analyses were well
reported for most trials. Quality of life was only assessed in
one RCT.24
Two RCTs24–27 did not report any methods of analyses,
seven RCTs19–23,29,30 reported using the log-rank test, and
four20–23 reported using Kaplan-Meier survival curves. In
addition, one trial25 reported using intention-to-treat analysis
and two20,22 reported using Cox models. For all but three
RCTs,24,28,30 survival curves were presented in the published
articles.
Of the 12 RCTs initially eligible for inclusion in the
systematic review, data on survival could be extracted from
seven trials,19–23,27,29 which included 988 patients and repre-
sented 75% of the randomized evidence. Two trials20,21 re-
ported long-term follow-up in addition to the initial results;
for data extraction, the articles that reported long-term fol-
low-up were used.31,32 The publications of four trials did not
contain enough data for extraction.24,26,28,30 The remaining
trial25 treated patients with either preoperative or postopera-
tive chemotherapy. However, there were only a few patients
who received preoperative chemotherapy, and these patients
were not reported independently from the patients who re-
ceived postoperative chemotherapy. Further details of all 12
eligible RCTs are shown in Tables 1 and 2.
Although subgroup analyses of patient-level character-
istics had been planned, data were limited and not reported in
a consistent way in the publications; thus, analysis was not
possible or advisable. In general, the RCTs consisted of
patients aged between 32 and 83 years, of which nearly 80%
were men with a good performance status. Half were of
squamous cell histologic type, and a quarter had adenocarci-
noma.
Overall Survival
Survival data were available for all seven RCTs (988
patients). For five RCTs,19,23,27,31,32 the only data available
were those extracted from the published curves. For one
trial,22 the p value and number of events and the published
curve were available; and for one trial,29 the hazard ratio and
confidence intervals were available. There was no clear
evidence of statistical heterogeneity (2 [6]  1.14; p  0.98;
I2  0) and therefore no obvious difference between trial
results, meaning that the trials were similar enough to be
combined.
Although the confidence intervals for individual trial
results were wide and the results of all trials are inconclusive,
all but one hazard ratio estimate were in favor of preoperative
chemotherapy (Figure 2).
The combined results showed a significant increase in
survival associated with the use of preoperative chemother-
apy (p 0.02). The hazard ratio of 0.82 (95% CI, 0.69–0.97)
represents an overall 18% relative reduction in the risk of
death on preoperative chemotherapy. This is equivalent to an
absolute improvement of 6% at 5 years, increasing overall
survival from 14% to 20%. However, survival varies by stage
of disease, and using the baseline survival from the various
FIGURE 2. Hazard ratio plot for overall survival. Each individual trial is represented by a square, the center of which denotes
the hazard ratio for that trial. The extremities of the horizontal bars denote the 99% CIs and the inner bars mark the 95% CIs.
The size of the square is directly proportional to the amount of information in the trial. The filled diamond at the bottom of
the plot gives an overall hazard ratio for the combined results of all trials. The center of the diamond denotes the hazard ratio
for all trials and the extremities the 95% CIs. Trials are ordered chronologically by the age of the trial, with the oldest listed
first.
L. A. Stewart and L. Rydzewska Journal of Thoracic Oncology • Volume 1, Number 7, September 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer616
stages gives a range in benefit of 3 to 7% for individual stages
of disease (Table 3).
As specified in the protocol, overall survival was also
analyzed using the random effects model. This resulted in the
same HR of 0.82 (95% CI, 0.69–0.97), as would be expected
with a set of very homogeneous trials.
Sensitivity Analysis for Overall Survival
The overall hazard ratio (HR  0.82) was very similar
to the hazard ratios of the two largest included RCTs (Depi-
erre et al.,22 HR  0.83; SWOG S9900,29 HR  0.84). To
ensure that the result of the meta-analysis was not being
driven entirely by the results of these two RCTs, a sensitivity
analysis was undertaken whereby these two RCTs were taken
out of the analysis. The hazard ratio for the remaining RCTs
was 0.79 (95% CI, 0.59–1.08) (Figure 3), which is reason-
ably similar to the hazard ratio for the overall result, and
almost reached statistical significance, but the confidence
intervals were wider, as there were fewer patients.
Overall Survival by Chemotherapy Type
As prespecified in the protocol, an analysis grouping
trials according to the type of chemotherapy given was also
performed. All patients received a platinum-based chemo-
therapy—either cisplatin or carboplatin—that was combined
with other agents. These other agents were split into the
following three groups, according to the way the chemother-
apy works: platinum plus vinca alkaloid/etoposide, platinum
plus taxane, and other platinum regimen. The results are
shown in Figure 4. The three groups all have very similar
hazard ratios, and no individual group is significant. The test
for interaction (2 [1]  0.12, p  0.99) indicates no clear
evidence of a difference of treatment effect shown by che-
motherapy group.
Overall Survival by Postoperative Treatment
Five of the seven trials reported that patients also
received postoperative treatment, which was either radiother-
apy or chemotherapy. An analysis could be performed at trial
level to detect any difference in the effect of neoadjuvant
treatment between the two groups of trials receiving addi-
tional radiotherapy or chemotherapy (i.e., was the observed
effect of preoperative chemotherapy influenced or moderated
by the postoperative therapy) (Figure 5). Where radiotherapy
was given postoperatively,23,27,32 it was given to patients on
TABLE 3. Five-Year Survival by Stage*
Stage
5-Year
Survival (%)
Absolute
Benefit (%)
New 5-Year
Survival (%)
Ia 75 4 79
Ib 55 6 61
IIa 50 7 57
IIb 40 7 47
IIIa 15–35 6–7 21–42
IIIb 5–10 3–5 8–15
*Figures for 5-year survival by stage as reported by van Zandwijk. 4
FIGURE 3. Hazard ratio plot for sensitivity
analysis for overall survival.
FIGURE 4. Hazard ratio plot for overall sur-
vival by chemotherapy grouping.
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both arms. However, when chemotherapy was given postop-
eratively,19,31 it was only given to those patients on the
preoperative chemotherapy arm. Because of this inconsis-
tency, and because of the small numbers of patients included,
this analysis should be viewed as exploratory.
The test for interaction (2 [1]  0.31, p  0.58)
indicates no clear evidence of a difference in the effectiveness
of preoperative chemotherapy, between those trials that gave
radiotherapy postoperatively and those that gave further che-
motherapy postoperatively.
Analysis of Other Outcomes
Of the prespecified additional outcomes, only disease-
free survival had sufficient data reported to allow analyses.
For this endpoint, data could be extracted from the publica-
tions of three RCTs23,29,32 (457 patients). Results (Figure 6)
showed a significant increase in disease-free survival associ-
ated with the use of preoperative chemotherapy (p  0.04).
The hazard ratio of 0.78 (95% CI, 0.52–0.99) represents an
overall 22% relative reduction in the risk of progression of
disease or death on preoperative chemotherapy. There was
some evidence of statistical heterogeneity, (2 [2] 5.42, p
0.07), and the I2 of 63% further suggested variability between
the trial results. However, it is difficult to draw conclusions
from this analysis, as it is based on only three trials and 457
patients (35% of eligible data). The results are undoubtedly
being driven by the results of the largest RCT,29 which
accounts for three-quarters of the patients included in this
analysis.
Toxicity and Quality-of-Life Assessment
Quality of life was not assessed in any of the seven
trials. There was, however, some information about toxicity
of the treatment. Three of the trials reported leukopenia,
anemia, alopecia, and nausea and vomiting to be common
mild side effects of the chemotherapy given. One further trial
reported that there were “no major toxic effects” associated
with chemotherapy. As these side effects were not reported as
severe, chemotherapy appears to have been well tolerated by
patients.
Tests for Publication Bias
A formal test for publication bias was carried out
(Figures 7 and 8). The p value from Begg’s test was 0.29 and
the p value from Egger’s test was 0.94, both suggesting there
was no significant publication bias. Begg’s funnel plot is
fairly symmetrical, with no clear indication that small nega-
tive studies are missing and thus does not suggest publication
FIGURE 5. Hazard ratio plot for overall sur-
vival by postoperative treatment.
FIGURE 6. Hazard ratio plot for disease-
free survival.
FIGURE 7. Begg’s and Egger’s tests for publication bias.
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bias. In fact, the plot might suggest that small studies in favor
of preoperative chemotherapy are missing. However, as the
number of trials included in this analysis is only seven, which
is less than the minimum recommended number of 10 trials,33
this analysis is likely to be unreliable. Also, we are already
aware that some trials (i.e., the five eligible but excluded
RCTs that have already been identified) are missing from the
analysis. Because these RCTs cannot be added to the test for
publication bias (as there are no results for them), it is not
clear where these would fit on Begg’s graph. However, from
this limited analysis, there is no indication of significant
publication bias among the included RCTs.
DISCUSSION
At the outset of this project, the question of whether
chemotherapy should be given before surgery in NSCLC had
not been formally addressed in a systematic review. Because
of the presence of large, ongoing trials or very recently closed
trials, it was decided that a systematic review and meta-
analysis of the published data should be carried out as a
means of summarizing current evidence on the effectiveness
of this intervention.
Unfortunately, the limitations of a systematic review
based on data extracted from published RCTs meant that
despite finding 12 eligible RCTs that included 1310 patients,
the meta-analysis was limited to data from only seven RCTs.
Of the five RCTs that could not be included, four RCTs did
not present relevant statistics or survival curves in the trial
report and one RCT could not be included, as the patients
who received preoperative chemotherapy were not reported
independently from those patients who were treated with
postoperative chemotherapy. The seven remaining RCTs in-
cluded 988 patients and represented 75% of the known
randomized evidence.
For the main endpoint of overall survival, the meta-
analysis showed a significant benefit to chemotherapy given
before surgery over surgery alone. This is equivalent to an
absolute benefit of 6% at 5 years. Although all trials random-
ized patients to chemotherapy and surgery versus surgery
alone, there was a wide range of treatments given postoper-
atively, sometimes in both arms, sometimes only in the
chemotherapy arm. There is no suggestion that preopera-
tive chemotherapy is more or less effective depending on
whether chemotherapy or radiotherapy was given after sur-
gery (test for interaction, 2 [1]  0.31; p  0.58). However,
data were only available for five of seven trials and included
only 298 patients; therefore, this result has low power, is
limited, and should be interpreted extremely cautiously.
There was also no suggestion that patients performed better
or worse depending on which type of chemotherapy they
were given preoperatively (p  0.99).
There was no suggestion of statistical heterogeneity
(p  0.98, I2  0) or publication bias (Begg’s test, p 0.29;
Egger’s test, p 0.94) in the results for overall survival.
There was more heterogeneity reported for disease-free sur-
vival (p  0.07, I2  63), but this analysis is very limited
because of the small number of RCTs and patients included.
No meaningful patient level subgroup analyses (e.g.,
whether the treatment is greater or less effective in early-
versus late-stage disease) could be performed on the basis of
the data reported in the publications. This illustrates the
difficulty of trying to explore patient-level characteristics
using aggregate data. The RCTs included in this review
reported patient-level characteristics in a number of different
ways, making comparisons between the trials impossible. The
only practical way to explore these patient subgroups is by
using individual patient data.
No formally measured quality-of-life data were re-
ported in any of the RCT publications; therefore, no conclu-
sions could be drawn beyond a description of the toxicity
reported that may have impacted on the patient’s quality of
life. There did not appear to be any serious toxicity associated
with chemotherapy from the information reported.
Eight of the 12 RCTs initially identified and six of the
seven RCTs included in this systematic review stopped early.
If recruitment to trials is stopped because of significant
differences between treatments or a “random high,” this can
lead to excessive false-positive results,34 but this problem can
be overcome to some extent by collecting extra follow-up
data. Two RCTs20,21 that stopped because of an observed
significant benefit on the preoperative chemotherapy arm
reported their results twice, both in 1994, then in 199831 and
1999.32 In both cases, the treatment effect lessened over time,
and in one case,20,31 the p value changed from p  0.01 to
p  0.06. The use of IPD would allow for the collection of
additional follow-up and the ongoing IPD meta-analysis may
go some way toward balancing this potential problem.
In August of 2005, when the literature searches were
carried out for a second time, a systematic review, by Bergh-
mans et al., of preoperative chemotherapy and surgery versus
surgery alone was identified.35 It reported six RCTs and 590
patients. It did not include two of the trials in this review.27,29
However, it did include one additional trial36 that had been
deemed ineligible for inclusion in this review. This additional
trial randomized patients to receive chemotherapy followed
by surgery plus chemotherapy versus surgery followed by
radiotherapy. This comparison was therefore confounded by
the inclusion of radiotherapy in just one arm so that it is not
possible to say whether any difference between arms is
FIGURE 8. Begg’s graph for publication bias.
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attributable to the addition of chemotherapy or radiotherapy
(Table 4). The overall fixed effect hazard ratio (calculated by
the Parmar method16) for the review by Berghmans is 0.69
(95% CI, 0.06–0.84), which is significantly in favor of
treatment. This is a more extreme result than the result of this
review (HR  0.82; 95% CI, 0.69–0.97), with some heter-
ogeneity (p 0.07). Because this review was completed after
the review by Berghmans et al., data have been included that
were made public in May of 2005, an inclusion of a further
398 patients.
Two further large RCTs have recently closed but are
not yet reported, and one large RCT is ongoing. One large
RCT29 included in this systematic review has only recently
been reported as an abstract. It is hoped that these RCTs will
be included in the ongoing IPD meta-analysis.
IPD meta-analyses are not reliant on published infor-
mation, and the ongoing IPD meta-analysis will allow the
inclusion of recently closed and ongoing trials. This will
bring the total number of RCTs that can potentially be
included to 15. IPD meta-analyses allow a more reliable
estimate and the collection of additional follow-up, which
may go some way toward addressing the potential problems
of RCTs that have stopped early. It will also allow other
outcomes such as disease-free survival to be investigated
further.
CONCLUSIONS
Although the systematic review reported here is lim-
ited, it represents a comprehensive and up-to-date systematic
review of the published data and suggests a significant sur-
vival benefit for patients with NSCLC who receive preoper-
ative chemotherapy compared with those who do not. The
value of this treatment will be assessed further through the
ongoing IPD meta-analysis.
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